DNA methyltransferases (DNMTs) are key enzymes that maintain DNA methylation.24 DNMT inhibitors can induce the re-expression of silenced tumor suppressors by decreasing DNA methylation levels.25 There are two FDA-approved DNMT inhibitors, 5-aza-2′-deoxycytidine (decitabine) and 5-aza-cytidine (azacitidine), which act as nucleoside analogs for incorporation into newly synthesized DNA strands.26 These two agents have been successfully used to treat myelodysplastic syndrome (MDS) and myeloid hematologic malignancies. The gene discussed is DNMT1; the disease is neoplasm.